Comparison of Chemoradiotherapy with Radiotherapy Alone in Patients with Esophageal Adenocarcinoma

Access this Article

Author(s)

Abstract

Despite the wide use of definitive chemoradiotherapy (CRT) for locally advanced esophageal adenocarcinoma, there is little evidence that CRT improves the survival of patients with esophageal adenocarcinoma compared with radiotherapy (RT) alone. Therefore, we retrospectively evaluated the outcome of patients with esophageal adenocarcinoma treated by CRT and RT alone. Patients were treated at the Gunma Prefectural Cancer Center (Ota, Japan) and the Gunma University Hospital (Maebashi, Japan). Patients provided written informed consent before treatment. Patients with distant metastases were excluded. CRT consisting of RT, nedaplatin, and 5-fluorouracil has been performed since 2002 when patients have adequate bone marrow, liver, and renal function. Between November 1993 and April 2006, 8 patients were treated by CRT and 12 were RT alone. The median follow-up period of surviving patients was 19 months. CRT group had a significantly higher complete response rate than those RT alone group (87% vs. 33%, <i>P</i> = 0.05). Of all patients, 2-year overall survival rate was 41% and the median survival time was 18 months. The 2-year overall survival of patients treated by CRT was 58%, significantly better than 24% of those with RT alone (<i>P</i> = 0.02). CRT can improve outcomes of patients with esophageal adenocarcinoma compared with RT alone.

Journal

  • Journal of Radiation Research

    Journal of Radiation Research 52(3), 264-269, 2011-05-16

    Journal of Radiation Research Editorial Committee

References:  32

Codes

  • NII Article ID (NAID)
    10028111008
  • NII NACSIS-CAT ID (NCID)
    AA00705792
  • Text Lang
    ENG
  • Article Type
    ART
  • ISSN
    04493060
  • NDL Article ID
    11088875
  • NDL Source Classification
    ZS45(科学技術--医学--放射線医学)
  • NDL Call No.
    Z53-P232
  • Data Source
    CJP  NDL  J-STAGE 
Page Top